Inspire Investing LLC Sells 11,246 Shares of Pulse Biosciences, Inc $PLSE

Inspire Investing LLC lessened its position in Pulse Biosciences, Inc (NASDAQ:PLSE) by 46.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,773 shares of the company’s stock after selling 11,246 shares during the quarter. Inspire Investing LLC’s holdings in Pulse Biosciences were worth $638,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PLSE. Osterweis Capital Management Inc. bought a new stake in Pulse Biosciences during the second quarter valued at about $28,000. Axxcess Wealth Management LLC acquired a new stake in shares of Pulse Biosciences in the third quarter valued at about $242,000. Bender Robert & Associates bought a new position in shares of Pulse Biosciences in the third quarter worth about $379,000. Jupiter Topco LLC bought a new position in shares of Pulse Biosciences in the second quarter worth about $241,000. Finally, GSA Capital Partners LLP bought a new position in shares of Pulse Biosciences in the second quarter worth about $290,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Trading Up 0.9%

Shares of PLSE stock opened at $53.67 on Thursday. The stock has a 50 day moving average of $50.82 and a two-hundred day moving average of $30.89. Pulse Biosciences, Inc has a 12 month low of $12.56 and a 12 month high of $58.90. The company has a market capitalization of $3.80 billion, a P/E ratio of -45.48 and a beta of 1.57.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. Sell-side analysts predict that Pulse Biosciences, Inc will post -1.34 earnings per share for the current fiscal year.

Insider Activity

In other Pulse Biosciences news, COO Liane Teplitsky acquired 1,036 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was bought at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the purchase, the chief operating officer owned 1,036 shares in the company, valued at $49,966.28. This represents a ? increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders have acquired 4,095 shares of company stock valued at $199,931. Corporate insiders own 74.00% of the company’s stock.

Wall Street Analysts Forecast Growth

PLSE has been the topic of several recent analyst reports. Canaccord Genuity Group lifted their price target on Pulse Biosciences from $43.00 to $58.00 and gave the stock a “buy” rating in a research report on Tuesday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, October 15th. Freedom Capital raised Pulse Biosciences to a “strong-buy” rating in a research report on Wednesday, September 9th. Oppenheimer boosted their target price on shares of Pulse Biosciences from $35.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 13th. Finally, Mizuho set a $55.00 target price on shares of Pulse Biosciences in a research note on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $60.20.

About Pulse Biosciences

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.